Three Drug Pricing Litigation Issues to Watch in the Second Half of ...

Further, the FTC seeks to lower prescription drug prices by curbing certain PBM practices, while vowing to revive the Robinson-Patman Act to do ...

Dan Latham on LinkedIn: Three Drug Pricing Litigation Issues to ...

Dan Latham's Post · Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP · More Relevant Posts · Three Drug Pricing ...

White & Case LLP on X: "In our latest alert, our Life Sciences and ...

In our latest alert, our Life Sciences and Healthcare lawyers discuss three drug pricing litigation issues to watch in the second half of ...

Julie McConnell on LinkedIn: Three Drug Pricing Litigation Issues to ...

Julie McConnell's Post · Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 | White & Case LLP · More Relevant Posts · Three Drug Pricing ...

Healthcare Matters on X: "Three Drug Pricing Litigation Issues to ...

Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 https://t.co/AVj70CiYKc | by @whitecase.

Eugene Hutchinson | Associate - White & Case LLP

His practice focuses on complex antitrust matters and counselling, with a specific focus on class action litigation at the cutting edge of pharmaceutical ...

FTC to sue three largest PBMs over drug price practices: WSJ

Antitrust regulators are set to file suit against CVS Caremark, Express Scripts and Optum Rx over how they negotiate discounts for drugs, including insulin.

Delisting, Pharmaceutical Patents, Drug Pricing - JD Supra

It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been ...

FTC Focus: How Scrutiny Of PBMs And Insulin May Play Out

This article is part of a monthly column that considers the significance of recent Federal Trade Commission announcements about antitrust ...

Biden's Action on Drug Pricing Set for Legal Battles in 2024

The pharmaceutical industry's resistance to the Biden administration's program for lowering what Medicare pays for costly drugs is expected to broaden this ...

FTC Sues Prescription Drug Middlemen for Artificially Inflating ...

Today, the Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, ...

Constitutional Challenges to the Medicare Drug Price Negotiation ...

117-169), which became law on August 16, 2022. The program allows Medicare to negotiate the prices of certain. Medicare drugs directly with drug ...

Recent Litigation Developments Regarding Drug Pricing and Access

By Rebecca Wolitz With multi-million dollar treatments entering the market, prescription drug costs accounting for between 15-17% of ...

FTC v Actavis and pricing practices spearhead rise in US ...

This article examines antitrust claims under the US Supreme Court's decision in FTC v Actavis for settlements of patent litigation involving alleged reverse ...

Significant 340B Drug Pricing Program Litigation May ... - Goodwin

Specifically: (1) new federal district court litigation challenging a recent HRSA Notice involving 340B Program “child site” registration and ...

Happy Birthday Two You, IRA: Drug Pricing Dynamics to Watch as ...

Key Takeaways: This week marks the second anniversary of the enactment of the Inflation Reduction Act, a partisan law that ushered in ...

Issue Brief: State Drug Pricing - ASHP

Both laws were challenged in court by drug companies. In April 2018, a federal appeals court ruled that Maryland's generic drug price gouging law is ...

FTC Releases Interim Staff Report on Prescription Drug Middlemen

The report finds that PBMs wield enormous power over patients' ability to access and afford their prescription drugs.

340B Drug Pricing Program - HRSA

This included waiver of longstanding requirements that off-site, outpatient hospital facilities be (1) listed as reimbursable on the hospital's ...

The Role of Pharmacy Benefit Managers in Prescription Drug Markets

2 As large health care conglomerates, some have argued that these. PBMs' vertical integration with insurers and pharmacies would better position ...